Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/178705
Title: Caveolin-1 is down-regulated in alveolar habdomyosarcomas and negatively regulates tumor growth
Author: Huertas-Martínez, Juan
Rello Varona, Santiago
Herrero Martín, David
Barrau, Ignasi
Garcia Monclús, Silvia
Sáinz-Jaspeado, Miguel
Lagares Tena, Laura
Núñez Álvarez, Yaiza
Mateo Lozano, Silvia
Mora Graupera, Jaume
Roma, Josep
Toran, Nuria
Moran, Sebastian
López Alemany, Roser
Gallego, Soledad
Esteller, Manel
Peinado Morales, Miguel Á. (Miguel Ángel)
García del Muro Solans, Xavier
Tirado, Oscar M.
Keywords: Metabolisme
Patologia
Tumors
Metabolism
Pathology
Tumors
Issue Date: 30-Oct-2014
Publisher: Impact Journals
Abstract: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with histological variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of less than 30%. Caveolin-1 (CAV1), encoding the structural component of cellular caveolae, is a suggested tumor suppressor gene involved in cell signaling. In the present study we report that compared to other forms of rhabdomyosarcoma (RMS) CAV1 expression is either undetectable or very low in ARMS cell lines and tumor samples. DNA methylation analysis of the promoter region and azacytidine-induced re-expression suggest the involvement of epigenetic mechanisms in the silencing of CAV1. Reintroduction of CAV1 in three of these cell lines impairs their clonogenic capacity and promotes features of muscular differentiation. In vitro, CAV1-expressing cells show high expression of Caveolin-3 (CAV3), a muscular differentiation marker. Blockade of MAPK signaling is also observed. In vivo, CAV1-expressing xenografts show growth delay, features of muscular differentiation and increased cell death. In summary, our results suggest that CAV1 could function as a potent tumor suppressor in ARMS tumors. Inhibition of CAV1 function therefore, could contribute to aberrant cell proliferation, leading to ARMS development.
Note: Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.2403
It is part of: Oncotarget, 2014, vol. 5, num. 20, p. 9744-9755
URI: http://hdl.handle.net/2445/178705
Related resource: https://doi.org/10.18632/oncotarget.2403
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
668676.pdf1.8 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons